European Society for Medical Oncology (ESMO) shared a post on LinkedIn:
“ESMOBreast26: Last 24 hours to share your studies! Contribute to a meeting recognised for its scientific depth and commitment to advancing breast cancer care. Don’t wait – submit now!
Deadline: 27 January 2026
Programme highlights will explore genetic testing, molecular profiling, biomarker-guided treatment, precision therapy, mechanisms of resistance, and the latest advances across ER-positive, HER2-positive, HER2-low, and TNBC disease. Survivorship and quality-of-life considerations will also be central to the discussions.
All accepted abstracts, including Late-breaking, will be published online in the ESMO Breast Cancer 2026 Abstract Book, a supplement to the official ESMO journal, ESMO Open.
At this event, you will be able to:
- Update your knowledge on the fast-developing field of breast cancer
- Understand the molecular biology of breast cancer and treatment-induced alterations
- Follow the developments in diagnostics, biomarkers, and treatments among the different subtypes of breast cancer
- Gain insights on risk-adapted strategies for optimising the treatment of breast cancer
- Understand the needs of special subgroups of patients with breast cancer.”
Proceed to the video attached to the post.
More posts featuring ESMO.